Skip to main content
. Author manuscript; available in PMC: 2015 Nov 2.
Published in final edited form as: Clin Immunol. 2014 Aug 19;155(1):60–70. doi: 10.1016/j.clim.2014.08.004

Table 2.

IgA anti-citrullinated HSP90 antibodies in BALF.

citHSP90αa citHSP90βa PP 1C–5Cb PP 6C–10Cb
RA-ILD (n = 8) 0 3c 2d 0
RA-subILD (n = 5) 0 0 0 0
RA-no ILD (n = 8) 0 0 1e 0
IPF (n = 5) 0 0 0 0
Healthy control (n = 5) 0 0 0 0

RA-ILD = RA with ILD, RA-subILD = RA with subclinical ILD (absence of cough, dyspnea), RA-no ILD = RA without ILD, IPF = idiopathic pulmonary fibrosis.

a

Positive responses based on OD450 threshold > 2 SD above the mean for healthy control subjects, using recombinant citrullinated HSP90α or citrullinated HSP90β as substrate antigen (1 µg/ml).

b

Positive responses based on OD450 threshold > 2 SD above the mean for healthy control subjects, using peptide pools (PP) consisting of 1C–5C or 6C–10C (5 peptides/pool, each at 0.2 µg/ml) as substrate antigens.

c

2/3 specimens also reactive to PP 1C–5C.

d

1/2 samples also positive for uncitrullinated peptide pool 1–5.

e

Specimen also positive for uncitrullinated peptide pool 1–5.